Literature DB >> 12952367

Evaluation of insulin resistance in acromegalic patients before and after treatment with somatostatin analogues.

C L Ronchi1, E Orsi, C Giavoli, V Cappiello, P Epaminonda, P Beck-Peccoz, M Arosio.   

Abstract

Many studies have recently shown that simple computer-solved indices, based on fasting glucose and insulin levels, closely mirror the euglycemic clamp technique in studying insulin resistance or pancreatic insulin secretion. Few data are at present available on the evaluation of these novel indices in acromegalic patients, known to be GH-dependent insulin-resistant subjects, in particular during medical treatment with somatostatin analogues. Indeed, these drugs are able to inhibit not only GH and IGF-I levels, but also insulin and glucagon pancreatic secretion, with contrasting effects on glucose metabolism. In this study, insulin resistance was evaluated by the homeostasis model assessment (HOMA-IR) and insulin sensitivity by quantitative insulin check index (QUICKI) in 27 normoglycemic acromegalic patients, before and after 6-month therapy with somatostatin analogues (lanreotide-SR 30-60 mg every 7-28 days in 15 and octreotide-LAR 20-30 mg every 28 days in 12). Thirty-five age- and sex-matched healthy subjects and 17 surgically treated acromegalic patients (5 cured and 12 not cured) were studied as control groups. Before medical treatment, HOMA-IR was higher in acromegalic patients than in healthy controls (4 +/- 3 vs 1.7 +/- 0.7, p < 0.05), while QUICKI was lower (0.33 +/- 0.04 vs 0.36 +/- 0.03, p < 0.05). During medical therapy, HOMA-IR decreased to 2.4 +/- 1.6 (p < 0.05) and became similar to that recorded in both healthy subjects and surgically treated patients. However, fasting glucose was increased and fasting insulin was decreased. QUICKI did not significantly change from basal values. No differences were observed between patients who normalized or not hormonal levels. The effects of the 2 drugs, though higher glucose levels were seen in patients treated with octreotide-LAR. In conclusion, this study demonstrates that medical treatment is able to improve insulin resistance, even if only successful surgery is able to completely normalize both HOMA-IR and QUICKI.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12952367     DOI: 10.1007/BF03345216

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  32 in total

1.  Is quantitative insulin sensitivity check index, a fair insulin sensitivity index in humans?

Authors:  J P Bastard; J J Robert; C Jardel; E Bruckert; A Grimaldi; B Hainque
Journal:  Diabetes Metab       Date:  2001-02       Impact factor: 6.041

2.  Homeostasis model assessment is a reliable indicator of insulin resistance during follow-up of patients with type 2 diabetes.

Authors:  A Katsuki; Y Sumida; E C Gabazza; S Murashima; M Furuta; R Araki-Sasaki; Y Hori; Y Yano; Y Adachi
Journal:  Diabetes Care       Date:  2001-02       Impact factor: 19.112

3.  Homeostasis model assessment of insulin resistance in relation to the incidence of cardiovascular disease: the San Antonio Heart Study.

Authors:  Anthony J G Hanley; Ken Williams; Michael P Stern; Steven M Haffner
Journal:  Diabetes Care       Date:  2002-07       Impact factor: 19.112

Review 4.  Acromegaly.

Authors:  S Melmed
Journal:  N Engl J Med       Date:  1990-04-05       Impact factor: 91.245

5.  Comparison of insulin sensitivity tests across a range of glucose tolerance from normal to diabetes.

Authors:  M P Hermans; J C Levy; R J Morris; R C Turner
Journal:  Diabetologia       Date:  1999-06       Impact factor: 10.122

6.  Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly.

Authors:  A Colao; D Ferone; P Marzullo; P Cappabianca; S Cirillo; V Boerlin; I Lancranjan; G Lombardi
Journal:  J Clin Endocrinol Metab       Date:  2001-06       Impact factor: 5.958

7.  Impaired beta-cell function in the presence of reduced insulin sensitivity determines glucose tolerance status in acromegalic patients.

Authors:  S Kasayama; M Otsuki; M Takagi; H Saito; S Sumitani; H Kouhara; M Koga; Y Saitoh; T Ohnishi; N Arita
Journal:  Clin Endocrinol (Oxf)       Date:  2000-05       Impact factor: 3.478

8.  Impact of octreotide, a long-acting somatostatin analogue, on glucose tolerance and insulin sensitivity in acromegaly.

Authors:  K K Ho; A B Jenkins; S M Furler; M Borkman; D J Chisholm
Journal:  Clin Endocrinol (Oxf)       Date:  1992-03       Impact factor: 3.478

9.  Insulin resistance in acromegaly: defects in both hepatic and extrahepatic insulin action.

Authors:  I Hansen; E Tsalikian; B Beaufrere; J Gerich; M Haymond; R Rizza
Journal:  Am J Physiol       Date:  1986-03

10.  Effects of treatment with octreotide in acromegalic patients--a multicenter Italian study. Italian Multicenter Octreotide Study Group.

Authors:  M Arosio; S Macchelli; C M Rossi; G Casati; O Biella; G Faglia
Journal:  Eur J Endocrinol       Date:  1995-10       Impact factor: 6.664

View more
  10 in total

1.  Effects of chronic slow release-lanreotide treatment on insulin-like growth factor system and metabolic parameters in acromegalic patients.

Authors:  V Gasco; G Beccuti; F Marotta; N Prencipe; M Maccario; J Janssen; A J van der Lely; E Ghigo; S Grottoli
Journal:  J Endocrinol Invest       Date:  2011-05-31       Impact factor: 4.256

Review 2.  Octreotide long-acting release (LAR): a review of its use in the management of acromegaly.

Authors:  Lily P H Yang; Gillian M Keating
Journal:  Drugs       Date:  2010-09-10       Impact factor: 9.546

3.  Glycometabolic control in acromegalic patients with diabetes: a study of the effects of different treatments for growth hormone excess and for hyperglycemia.

Authors:  V M Cambuli; M Galdiero; M Mastinu; F Pigliaru; R S Auriemma; A Ciresi; R Pivonello; M Amato; C Giordano; S Mariotti; A Colao; M G Baroni
Journal:  J Endocrinol Invest       Date:  2011-04-28       Impact factor: 4.256

Review 4.  Medical therapy of acromegaly in Turkey.

Authors:  O Celik; P Kadioglu
Journal:  J Endocrinol Invest       Date:  2010-09       Impact factor: 4.256

Review 5.  Medical consequences of acromegaly: what are the effects of biochemical control?

Authors:  Annamaria Colao; Renata S Auriemma; Rosario Pivonello; Mariano Galdiero; Gaetano Lombardi
Journal:  Rev Endocr Metab Disord       Date:  2008-03       Impact factor: 6.514

6.  Long-term effects of the combination of pegvisomant with somatostatin analogs (SSA) on glucose homeostasis in non-diabetic patients with active acromegaly partially resistant to SSA.

Authors:  Laura De Marinis; Antonio Bianchi; Alessandra Fusco; Vincenzo Cimino; Marilda Mormando; Laura Tilaro; Gherardo Mazziotti; Alfredo Pontecorvi; Andrea Giustina
Journal:  Pituitary       Date:  2007       Impact factor: 4.107

7.  HOMA-IR in acromegaly: a systematic review and meta-analysis.

Authors:  Betina Biagetti; Anna Aulinas; Anna Casteras; Santiago Pérez-Hoyos; Rafael Simó
Journal:  Pituitary       Date:  2020-10-21       Impact factor: 4.107

8.  Efficacy and safety of 48 weeks of treatment with octreotide LAR in newly diagnosed acromegalic patients with macroadenomas: an open-label, multicenter, non-comparative study.

Authors:  S Grottoli; R Celleno; V Gasco; R Pivonello; D Caramella; A Barreca; F Ragazzoni; F Pigliaru; D Alberti; R Ferrara; G Angeletti
Journal:  J Endocrinol Invest       Date:  2005-12       Impact factor: 4.256

9.  Therapeutic options in the management of acromegaly: focus on lanreotide Autogel.

Authors:  Ferdinand Roelfsema; Nienke R Biermasz; Alberto M Pereira; Johannes A Romijn
Journal:  Biologics       Date:  2008-09

10.  Metabolic Fingerprint of Acromegaly and its Potential Usefulness in Clinical Practice.

Authors:  Betina Biagetti; J R Herance; Roser Ferrer; Anna Aulinas; Martina Palomino-Schätzlein; Jordi Mesa; J P Castaño; Raul M Luque; Rafael Simó
Journal:  J Clin Med       Date:  2019-09-26       Impact factor: 4.241

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.